<?xml version="1.0" encoding="UTF-8"?>
<clinical_study>
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 09, 2025</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT00070733</url>
  </required_header>
  <id_info>
    <org_study_id>R01HD043348-01</org_study_id>
    <nct_id>NCT00070733</nct_id>
  </id_info>
  <brief_title>The Effect of 5-Alpha Reductase on Testosterone in Men</brief_title>
  <official_title>The Role of 5-Alpha Reductase in Mediating Testosterone Actions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</source>
  <brief_summary>
    <textblock>The enzyme 5-alpha reductase is present in small amounts in muscle and converts&#xd;
testosterone to dihydrotestosterone (DHT). Testosterone affects lean body tissue, muscle&#xd;
size, muscle strength, and sexual function in men. This study will evaluate how 5-alpha&#xd;
reductase influences the effects of testosterone in young healthy men.</textblock>
  </brief_summary>
  <detailed_description>
    <textblock>Testosterone, the predominant circulating androgen in men, serves as the active hormone&#xd;
in some target tissues; however, testosterone effects in other target organs require its&#xd;
conversion to two active metabolites, estradiol 17-beta and DHT. The role of 5-alpha&#xd;
reductase in mediating testosterone's effects on muscle and sexual function remains&#xd;
unclear. This study will determine whether 5-alpha reduction of testosterone to DHT is&#xd;
necessary for mediating effects on fat-free mass, muscle size, muscle strength, and leg&#xd;
power in men. The study will also evaluate the necessity of 5-alpha reductase for&#xd;
maintenance of androgen effects on sexual function (sexual desire, overall sexual&#xd;
activity, nocturnal penile tumescence [NPT], response to visual erotic stimulus, and&#xd;
penile rigidity) in men.&#xd;
&#xd;
Participants in this study will be treated with a drug to suppress endogenous&#xd;
testosterone production. Participants will then be randomly assigned to receive either&#xd;
testosterone and placebo or testosterone and the 5-alpha reductase inhibitor dutasteride.&#xd;
Testosterone will be administered weekly; dutasteride and placebo will both be&#xd;
administered daily. Diet and exercise will be standardized across both groups.&#xd;
Participants will be assessed at study entry and Week 20. Assessments will include&#xd;
measurements such as a DEXA scan, MRI scan, and muscle performance and sexual function&#xd;
tests. Participants will also have blood tests for safety monitoring; blood tests will&#xd;
include measures of hematocrit, liver enzymes (AST and ALT), prostate specific antigen&#xd;
(PSA), and cholesterol.</textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2003</start_date>
  <completion_date>June 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>184</enrollment>
  <condition>Sex Disorders</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>testosterone enanthate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>duastride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>Inclusion Criteria&#xd;
&#xd;
  -  General good health and capable of undergoing strength testing&#xd;
&#xd;
  -  Normal testosterone (300-1100 ng/dL), LH, and FSH levels&#xd;
&#xd;
Exclusion Criteria&#xd;
&#xd;
  -  Currently participating in competitive sports&#xd;
&#xd;
  -  Mental state that would preclude complete understanding of the protocol and&#xd;
     compliance&#xd;
&#xd;
  -  Disorder known to cause or be associated with hypogonadism (e.g., pituitary tumors,&#xd;
     hyperprolactinemia, HIV infection, or Klinefelter's Syndrome)&#xd;
&#xd;
  -  More than 20% over ideal body weight&#xd;
&#xd;
  -  Disabilities that would prevent participation in strength testing (e.g., amputation&#xd;
     of limbs, blindness, severe arthritis, angina, or neurologic disorders such as&#xd;
     Parkinson's disease, stroke, or myopathy)&#xd;
&#xd;
  -  Uncontrolled hypertension, diabetes, congestive heart failure, or chronic&#xd;
     obstructive lung disease&#xd;
&#xd;
  -  Alcohol or drug dependence in the 6 months prior to study entry&#xd;
&#xd;
  -  Disorders that might be exacerbated by androgen treatment (e.g., benign prostatic&#xd;
     hyperplasia or prostate cancer, erythrocytosis [hematocrit > 51% at baseline], or&#xd;
     sleep apnea assessed by Berlin's questionnaire)&#xd;
&#xd;
  -  Serum PSA levels > 4 microg/L&#xd;
&#xd;
  -  AST, ALT, or alkaline phosphatase elevation greater than three times the upper limit&#xd;
     of normal&#xd;
&#xd;
  -  Creatinine greater than 2 mg/dL&#xd;
&#xd;
  -  Medications that might affect muscle or bone metabolism (e.g., glucocorticoid, rhGH,&#xd;
     androgenic steroids, oral androgen precursors such as androstenedione or DHEA) or&#xd;
     androgen metabolism, action, or clearance (e.g., dilantin, phenobarbitol, aldactone,&#xd;
     flutamide, finasteride)</textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shalender Bhasin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charles R. Drew University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Charles R. Drew University</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90059</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shalender Bhasin, MD</last_name>
      <phone>323-563-9353</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2003</verification_date>
  <study_first_submitted>October 7, 2003</study_first_submitted>
  <study_first_submitted_qc>October 9, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2003</study_first_posted>
  <last_update_submitted>November 4, 2005</last_update_submitted>
  <last_update_submitted_qc>November 4, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 7, 2005</last_update_posted>
  <keyword>Testosterone</keyword>
  <keyword>5-alpha Reductase</keyword>
  <keyword>Muscle Strength</keyword>
  <keyword>Libido</keyword>
  <keyword>Sexual Function</keyword>
  <keyword>Muscle Mass</keyword>
  <keyword>Testosterone 5-alpha-Reductase</keyword>
  <condition_browse>
    <mesh_term>Sexual Dysfunction, Physiological</mesh_term>
  </condition_browse>
  <intervention_browse>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
  </intervention_browse>
</clinical_study>
